Premium
Mammalian target of rapamycin expression and laryngeal squamous cell carcinoma prognosis: novel preliminary evidence
Author(s) -
Marioni Gino,
Staffieri Alberto,
Giacomelli Luciano,
Lionello Marco,
Guzzardo Vincenza,
Busnardo Alessandra,
Blandamura Stella
Publication year - 2011
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2011.03864.x
Subject(s) - pi3k/akt/mtor pathway , medicine , oncology , multivariate analysis , discovery and development of mtor inhibitors , cancer research , angiogenesis , basal cell , cancer , apoptosis , biology , biochemistry
Marioni G, Staffieri A, Giacomelli L, Lionello M, Guzzardo V, Busnardo A & Blandamura S
(2011) Histopathology 58, 1148–1156
Mammalian target of rapamycin expression and laryngeal squamous cell carcinoma prognosis: novel preliminary evidence Aims: The mammalian target of rapamycin (mTOR) has a key role in regulating cancer cell proliferation, apoptosis, cell migration, and angiogenesis. The aim of this study was to assess the relationships between mTOR and clinicopathological and prognostic parameters in laryngeal squamous cell carcinoma (SCC). Methods and results: Mammalian target of rapamycin expression was determined in 103 consecutive operable laryngeal SCCs. Among the mTOR‐positive cases, the locoregional recurrence rate was higher ( P = 0.048) and the disease‐free survival (DFS) rate was shorter ( P = 0.031) in patients with mTOR expression >50.7%. In the N 0 subgroup, the disease recurrence rate was higher ( P = 0.034) and the DFS was shorter ( P = 0.009) in patients with mTOR expression >50.7%. In mTOR‐positive patients, multivariate analysis showed that N stage ( P = 0.0001) and mTOR status ( P = 0.042) were independent indicators of a poor prognosis. Conclusions: mTOR appeared to be a significant predictor of DFS in univariate and multivariate models. mTOR expression in laryngeal SCC may be useful for the detection of patients at higher risk for recurrence, and N 0 patients at higher risk for early locoregional recurrence who might benefit from more aggressive therapy. The role of mTOR inhibitors in multimodality or multitarget strategies against laryngeal SCC warrants investigation.